HD-OPM Archive
Topics › Plaque, CAC & CT angiography

Atherogenic index of plasma (log TG/HDL) predicts rapid plaque progression in PARADIGM

Louis Nervegna · Apr 10, 2026 · ♥ 5 reactions · 18 comments · original Facebook post
Plaque, CAC & CT angiographyLDL, ApoB & lipid panel
AI summary & key facts

A PARADIGM sub-study found higher AIP, the base-10 log of triglycerides divided by HDL, was associated with faster plaque progression and greater plaque burden in diabetic and non-diabetic adults. Rapid plaque progression occurred in 26.1% over a median 3.4 years of follow-up.

The ratio of triglycerides to HDL is associated with the rate at which plaque progresses in non-diabetics.

These results come from the PARADIGM study.

Link to journal paper:

“Association between atherogenic index of plasma and rapid progression of coronary atherosclerosis in non-diabetic and diabetic adults: Insight from the PARADIGM study” (JCCT, Apr. 2026)

journalofcardiovascularct.comLink to journalofcardiovascularct.comjournalofcardiovascularct.com

Technically, they used a marker called AIP, which is the base 10 logarithm of TG/HDL:

AIP = log10(TG/HDL)

See comments for more details. The acronym AIP stands for Atherogenic Index of Plasma.

Quoted from the journal paper:

“During a median follow-up of 3.4 years, the incidence of RPP [Rapid Plaque Progression] was 26.1%. Compared with non-diabetic subjects, diabetic subjects exhibited significantly higher AIP levels, larger baseline plaque burden, and higher RPP incidence. After adjusting for age, sex, hypertension, overweight or obesity, current smoking, low-density lipoprotein cholesterol and creatinine levels, baseline total PAV, and the use of aspirin, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, or statins, AIP (per 0.1-unit increase) was associated with the risk of RPP in non-diabetic subjects (odds ratio [OR] 1.07, 95% confidence interval [CI] 1.01−1.13; p ​< ​0.05) but not in diabetic subjects (OR 1.04, 95% CI 0.95−1.14; p ​= ​0.430).”

“AIP is independently associated with the risk of RPP [Rapid Plaque Progression] in the absence of established diabetes. This finding suggests that AIP may be an effective biomarker for predicting RPP in the population of non-diabetic adults.”

My note:

This is only an association. AIP and TG/HDL can be used to help assess risk, but they are likely not causal in and of themselves. They act as a crude proxy for insulin sensitivity and metabolic health (which are causal), both of which can be measured more accurately by other tests (such as an OGTT with insulin). The best way to improve AIP and TG/HDL is to lose visceral fat and clear the liver and pancreas of ectopic fat. See this post on the subject: ↪ Triglycerides and TG/HDL as markers of insulin resistance and visceral fat.

Higher AIP and TG/HDL do predict smaller LDL particle size, but smaller particle size loses its ability to determine risk once total number of particles is properly accounted for (e.g. by measuring ApoB). See this post: ↪ LDL particle size adds nothing once LDL-P or ApoB is known. In other words, what higher AIP and TG/HDL is really doing when acting as a marker for small particle size is that they are predicting higher ApoB overall.

#tghdlratioHD #paradigmHD #aipHD #plaqueHD #triglyceridesHD #hdlHD #liverfatHD

Research cited

🔥 Not all lipids are created equal… and not all risk is visible—until now.
PARADIGM study insight into metabolic drivers of CAD

This PARADIGM study dives into something simple—but powerful:
👉 the Atherogenic Index of Plasma (AIP)
(a ratio reflecting triglycerides and HDL balance)

And asks a critical question:
Can it predict rapid progression of coronary atherosclerosis?

The answer is: yes—and more than you might expect.

📊 Across both diabetic and non-diabetic patients, higher AIP levels were strongly associated with:

💡 And here’s the key insight:
This association holds independently of traditional risk factors.

Not just LDL.
Not just diabetes.
Not just “risk scores”.

👉 AIP captures something different:
A more dynamic, metabolic, and atherogenic environment.

Even more interesting 👇
Patients with higher AIP didn’t just have more plaque…
They had plaque that evolved faster.

⚠️ That’s a completely different clinical problem.

Because progression—not just presence—is what drives events.

🚨 Let’s be honest:
We’ve been obsessed with static snapshots of risk
while the disease is continuously evolving.

This study reminds us that:
👉 The biology of atherosclerosis is active, metabolic, and time-dependent.

🧠 So what’s the takeaway?

🚀 The future?
Not just treating numbers.
Not just detecting plaque.

👉 But identifying who is progressing—and why.

That’s where real prevention begins.

No photo description available.
← newer: Plant-based diet quality and dementia: whole plant foods proolder: Sumo wrestlers avoid obesity diseases by storing little live →